23 reports of this reaction
1.4% of all BIVALIRUDIN reports
#13 most reported adverse reaction
HAEMORRHAGE INTRACRANIAL is the #13 most commonly reported adverse reaction for BIVALIRUDIN, manufactured by Accord Healthcare, Inc.. There are 23 FDA adverse event reports linking BIVALIRUDIN to HAEMORRHAGE INTRACRANIAL. This represents approximately 1.4% of all 1,699 adverse event reports for this drug.
Patients taking BIVALIRUDIN who experience haemorrhage intracranial should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE INTRACRANIAL is a less commonly reported adverse event for BIVALIRUDIN, but still significant enough to appear in the safety profile.
In addition to haemorrhage intracranial, the following adverse reactions have been reported for BIVALIRUDIN:
The following drugs have also been linked to haemorrhage intracranial in FDA adverse event reports:
HAEMORRHAGE INTRACRANIAL has been reported as an adverse event in 23 FDA reports for BIVALIRUDIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE INTRACRANIAL accounts for approximately 1.4% of all adverse event reports for BIVALIRUDIN, making it a notable side effect.
If you experience haemorrhage intracranial while taking BIVALIRUDIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.